• Je něco špatně v tomto záznamu ?

Beta-adrenergic drugs and risk of Parkinson's disease: A systematic review and meta-analysis

A. Singh, S. Hussain, S. Akkala, J. Klugarová, A. Pokorná, M. Klugar, EH. Walters, I. Hopper, JA. Campbell, B. Taylor, B. Antony

. 2022 ; 80 (-) : 101670. [pub] 20220617

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, metaanalýza, přehledy, systematický přehled, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024497

BACKGROUND: Parkinson's Disease (PD) is a neurodegenerative disorder manifested by rest tremor, rigidity, bradykinesia, and postural instability. Recent pharmaco-epidemiological studies evaluating beta-adrenergic drug use and risk of PD have reported conflicting findings. OBJECTIVES: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. METHODS: An electronic literature search of eight databases was performed from inception to July 2021 to identify pharmaco-epidemiological studies (case-control and cohort) reporting the risk of PD in beta-adrenergic users compared to non-users. We used the generic inverse variance method and RevMan (5.3.5) to estimate pooled adjusted risk ratios (aRRs) of PD using a random-effects model. RESULTS: Of 3168 records, 15 studies (10 case-control; five cohort) with 6508,877 participants, including 87,011 PD cases, were included. In the pooled analysis (n = 10) including any beta-antagonist users, compared with non-users, the aRR for PD was 1.19 (CI: 1.05,1.35); for any beta-agonist users (n = 8) aRR for PD was 0.87 (CI: 0.78,0.97). Propranolol users had a significantly increased risk of PD (aRR:1.91; CI:1.20,3.06), whereas salbutamol use was associated with reduced risk of PD (aRR:0.95; CI:0.92,0.99). Significant heterogeneity (I2 >87%) was observed, but the majority (n = 13) of the studies were of high quality, based on the JBI tool. CONCLUSIONS: Beta-antagonist use was associated with a modestly increased risk of PD, whereas beta-agonist use was associated with a modest decreased risk of PD. Future epidemiological studies should address the issues of protopathic bias and indirect association using appropriate epidemiological methods.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024497
003      
CZ-PrNML
005      
20221031100316.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.arr.2022.101670 $2 doi
035    __
$a (PubMed)35718329
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Singh, Ambrish $u Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia
245    10
$a Beta-adrenergic drugs and risk of Parkinson's disease: A systematic review and meta-analysis / $c A. Singh, S. Hussain, S. Akkala, J. Klugarová, A. Pokorná, M. Klugar, EH. Walters, I. Hopper, JA. Campbell, B. Taylor, B. Antony
520    9_
$a BACKGROUND: Parkinson's Disease (PD) is a neurodegenerative disorder manifested by rest tremor, rigidity, bradykinesia, and postural instability. Recent pharmaco-epidemiological studies evaluating beta-adrenergic drug use and risk of PD have reported conflicting findings. OBJECTIVES: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. METHODS: An electronic literature search of eight databases was performed from inception to July 2021 to identify pharmaco-epidemiological studies (case-control and cohort) reporting the risk of PD in beta-adrenergic users compared to non-users. We used the generic inverse variance method and RevMan (5.3.5) to estimate pooled adjusted risk ratios (aRRs) of PD using a random-effects model. RESULTS: Of 3168 records, 15 studies (10 case-control; five cohort) with 6508,877 participants, including 87,011 PD cases, were included. In the pooled analysis (n = 10) including any beta-antagonist users, compared with non-users, the aRR for PD was 1.19 (CI: 1.05,1.35); for any beta-agonist users (n = 8) aRR for PD was 0.87 (CI: 0.78,0.97). Propranolol users had a significantly increased risk of PD (aRR:1.91; CI:1.20,3.06), whereas salbutamol use was associated with reduced risk of PD (aRR:0.95; CI:0.92,0.99). Significant heterogeneity (I2 >87%) was observed, but the majority (n = 13) of the studies were of high quality, based on the JBI tool. CONCLUSIONS: Beta-antagonist use was associated with a modestly increased risk of PD, whereas beta-agonist use was associated with a modest decreased risk of PD. Future epidemiological studies should address the issues of protopathic bias and indirect association using appropriate epidemiological methods.
650    _2
$a adrenergní látky $7 D018663
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kohortové studie $7 D015331
650    _2
$a lidé $7 D006801
650    12
$a Parkinsonova nemoc $x farmakoterapie $x epidemiologie $7 D010300
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a přehledy $7 D016454
655    _2
$a systematický přehled $7 D000078182
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hussain, Salman $u Czech National Centre for Evidence-Based Healthcare and Knowledge Translation, (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Akkala, Sreelatha $u Independent researcher, Bangalore, India
700    1_
$a Klugarová, Jitka $u Czech National Centre for Evidence-Based Healthcare and Knowledge Translation, (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Pokorná, Andrea $u Czech National Centre for Evidence-Based Healthcare and Knowledge Translation, (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Nursing and Midwifery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Klugar, Miloslav $u Czech National Centre for Evidence-Based Healthcare and Knowledge Translation, (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Walters, E Haydn $u Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia; Emeritus Director Respiratory Medicine, and VMO Acute Medicine, The Alfred Hospital, Melbourne
700    1_
$a Hopper, Ingrid $u School of Public Health and Prevention Medicine, Monash University, Melbourne, Victoria, Australia
700    1_
$a Campbell, Julie A $u Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia
700    1_
$a Taylor, Bruce $u Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia; Department of Neurology, Royal Hobart Hospital, Hobart, Australia
700    1_
$a Antony, Benny $u Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia. Electronic address: benny.eathakkattuantony@utas.edu.au
773    0_
$w MED00008553 $t Ageing research reviews $x 1872-9649 $g Roč. 80, č. - (2022), s. 101670
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35718329 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100314 $b ABA008
999    __
$a ok $b bmc $g 1854293 $s 1175787
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 80 $c - $d 101670 $e 20220617 $i 1872-9649 $m Ageing research reviews $n Ageing Res Rev $x MED00008553
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace